TEL AVIV, Israel, Sept. 19, 2013 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), today announced that the Company will be presenting at the Aegis Capital 2013 Annual Healthcare Conference. The conference is being held at The Encore at Wynn Las Vegas.
Yaron Daniely, Chief Executive Officer of Alcobra, is scheduled to present at 10:15 a.m. PT on Thursday, September 26th. The presentation will not be webcast, however investors attending the conference interested in meeting with management should contact their Aegis Capital representative.
About Alcobra Ltd.
Alcobra Ltd. is an emerging biopharmaceutical company primarily focused on the development and commercialization of a proprietary drug, MG01CI, to treat Attention Deficit Hyperactivity Disorder (ADHD). MG01CI has completed Phase II studies to treat Attention Deficit Hyperactivity Disorder. The company was founded in 2008 and is headquartered in Tel Aviv, Israel.
CONTACT: U.S. Investor Contacts: KCSA Strategic Communications Jeffrey Goldberger / Garth Russell +1 212.896.1249 / +1 212.896.1250 email@example.com / firstname.lastname@example.org Israel Investor Contact: Investor Relations Ltd. Moran Meir-Beres +011972-3-5167620 email@example.comSource:Alcobra Ltd.